FULL APPROVAL

FDA grants full PMA approval to Artivion's AMDS aortic dissection device

The approval eliminates the humanitarian-exemption IRB requirement and rests on PERSEVERE data showing a 72% relative cut in 30-day mortality versus hemiarch repair alone.

By AppliedXLJune 29, 2026Trial NCT05174767

Executive Summary

The FDA granted full premarket approval for a device already sold under a narrower emergency-use exemption, removing the hospital-by-hospital review step that exemption required.
The approval rests on a single-arm device trial that reported reductions in early mortality and complications against a historical surgical comparator, with two-year follow-up showing the benefit held without new safety signals.
The trial's non-randomized design and reliance on relative rather than absolute outcome measures mean the reported effect sizes should be read as supportive rather than definitive.
The device already has commercial and clinical infrastructure in place from its prior limited authorization, positioning the sponsor to expand use quickly now that the broader approval is in hand.

The decision

Artivion, Inc. announced on June 29, 2026, that the FDA approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis, covering acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion, a population the company estimates at roughly 60% of all DeBakey Type I dissections. The device had been sold since an earlier clearance under a Humanitarian Device Exemption (HDE), which required each hospital to secure its own institutional review board sign-off before implanting the device; the new PMA eliminates that requirement. Artivion first told investors it expected PMA approval in the second half of 2025, a window that closed December 31, 2025; the decision landed on June 29, 2026, roughly six months after that stated window. Artivion+1

Probability of Success

Endpoint Met57%

Completes81%

Clinical Significance10%

Regulatory83%

The trial behind it

The approval is built on PERSEVERE (NCT05174767), a prospective, multicenter, non-randomized trial in 115 patients with acute DeBakey Type I dissection and malperfusion, run against a comparator of historical hemiarch-repair outcomes rather than a concurrent control arm. At 30 days, the trial reported a 72% relative reduction in all-cause mortality and a 54% relative reduction in the composite of major adverse events, including stroke, renal failure requiring dialysis, and myocardial infarction, alongside zero cases of distal anastomotic new entry (DANE) tears, a complication the company says occurs in up to 45% to 70% of hemiarch-repair patients without the device. Two-year follow-up data presented at the Society of Thoracic Surgeons' 62nd Annual Meeting in February 2026 showed the absence of DANE tears held, with no additional unanticipated aortic reoperations and stable aortic dimensions. NCT05174767+2

Reading the numbers

The trial's own one-year late-breaking data, presented at the Society's 61st Annual Meeting in January 2025, put absolute mortality at 20.4% at one year against 42.7% in the historical-control cohort, and disabling stroke at 11.8% against 20.9%. Those are the absolute figures behind the relative reductions the company cited at PMA approval. The design carries no randomized concurrent arm, so the comparison rests on historical rates rather than a trial-matched control group, a limitation the company's own disclosures flag alongside the relative-only framing of the headline reduction figures. Artivion+1

Operational picture

The trial closed enrollment at 115 patients, unchanged from its most recent target, and moved to Active, not recruiting status in January 2025 once enrollment completed. Enrollment target increased from 93 to 133 in August 2024 before settling at 115 patients, and the primary completion date moved twice before landing on December 11, 2023. Chairman, President and Chief Executive Officer Pat Mackin said the approval "not only validates the enduring benefits shown in the PERSEVERE clinical data but also removes a barrier to broader adoption by eliminating the IRB requirement that came with the HDE". NCT05174767+1

Competitive position

AMDS has no direct comparator sharing its target or mechanism in this indication; the nearest precedent in the competitive field is Artivion's own earlier AMDS trial (NCT03397251), a prior study of the same device rather than a rival program. The broader DeBakey Type I dissection landscape carries limited registered competitive activity, with the only other identified device trial in the adjacent Type B dissection setting run by a different sponsor. That sparsity means the approval's competitive consequence is largely about how far AMDS itself can now be adopted, rather than displacing a rival mechanism. NCT05174767

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.